By FieldPulse Staff · March 22, 2026
Tags: policy, drug-pricing, cms, formulary
The Trump administration's push to codify Most Favored Nation drug pricing into law is fracturing Republican support in Congress, even as pharma faces simultaneous pressure from CMS Round 3 negotiations and new pricing agreements. The outcome will determine the commercial model for every specialty drug in America.
The most consequential drug pricing battle in a decade is playing out across Washington in real time — and the outcome will shape how every pharmaceutical rep's portfolio is priced, covered, and contracted for the foreseeable future. The Trump administration has been aggressively pushing to codify Most Favored Nation (MFN) drug pricing into law. Under MFN, U.S. prices for branded pharmaceuticals would be capped at the lowest prices paid by comparable OECD nations — effectively ending the longstanding model in which the U.S. subsidizes global drug development by paying two to four times what ot